Skip to main content
Parnax Lab Limited logo

Parnax Lab Limited — Investor Relations & Filings

Ticker · 506128 ISIN · INE383L01019 BSE.NS Manufacturing
Open in API
Filings indexed 286 across all filing types
Latest filing 2026-05-20 Regulatory Filings
Country IN India
Listing BSE.NS 506128

About Parnax Lab Limited

https://naxparlab.com

Parnax Lab Limited specializes in the development and large-scale manufacturing of pharmaceutical formulations, with a primary focus on liquid orals, ointments, creams, and gels. The company operates advanced production facilities compliant with international quality benchmarks, including WHO-GMP standards. It functions as a contract development and manufacturing organization (CDMO), providing end-to-end solutions from formulation development to commercial production for global and domestic healthcare brands. The product range encompasses diverse therapeutic areas such as dermatology, gastrointestinal health, and pediatric care. By integrating modern technology with rigorous quality control processes, the company ensures the delivery of high-stability medicinal products. Its operations are supported by a dedicated research and development wing focused on optimizing delivery systems and enhancing product efficacy for various clinical applications.

Recent filings

Filing Released Lang Actions
Parnax Lab Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2026 ,inter alia, to consider and approve Standalone and Consolidated Audited ....
Regulatory Filings Classification · 88% confidence The document is a notice of a board meeting under Regulation 29 of the Listing Obligation and Disclosure Requirements. It does not announce changes in board composition nor does it contain actual financial results—it simply informs the exchange of the meeting date to approve results. This is a routine regulatory announcement rather than the report itself or a management change. Therefore, it falls under Regulatory Filings (RNS).
2026-05-20 English
Please find enclosed herewith the Compliance Certificate under regulation 74(5) of SEBI (DP) Regulation, 2018.
Regulatory Filings Classification · 95% confidence The document is a confirmation certificate issued by MUFG Intime India Private Limited under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018. It confirms the dematerialisation of securities for the quarter ended 31st March 2026, including acceptance/rejection of securities and cancellation of certificates. The document is a regulatory compliance confirmation and does not contain financial statements, management discussion, or any report content. It is short (2151 characters) and serves as a regulatory filing rather than a financial or management report. Therefore, it fits best under Regulatory Filings (RNS).
2026-04-08 English
Financial Results for the Quarter Ended December 31, 2025.
Regulatory Filings
2026-02-13 English
Outcome of Board Meeting for Considered and Approved the Standalone & Consolidated Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2025
Regulatory Filings
2026-02-13 English
Compliance Certificate under Reg 74 (5) of SEBI (DP) Regulations, 2018 for quarter ended 31st December, 2025
Regulatory Filings
2026-01-22 English
Intimation of Closure of Trading Window for the quarter and nine months ended 31st December, 2025 and shall open 48 hours after the Unaudited Financials Results become generally available ....
Regulatory Filings
2025-12-31 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.